

JEW

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/749,706	
	Filing Date	December 31, 2003	
	First Named Inventor	George F. SCHREINER	
	Art Unit	1647	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	6	Attorney Docket Number	219002030902

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 (2 pages) Return Postcard
Remarks CUSTOMER NO. 25225		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP James J. Mullen, III - 44,957
Signature	
Date	July 29, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: July 29, 2004	Signature: (Rhea Amid)



PATENT
Docket No. 219002030902

CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on July 29, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

George F. SCHREINER et al.

Serial No.: 10/749,706

Filing Date: December 31, 2003

For: METHODS OF TREATING
HYPERTENSION AND
COMPOSITIONS FOR USE THEREIN

Examiner: Not Yet Assigned

Group Art Unit: 1647

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action directed to the related application Serial Number 09/392,932 filed 9 September 1999 and issued as U.S. Patent No. 6,352,975 on 5 March 2002; accordingly, copies are not included

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 219002030902. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 22, 2004

Respectfully submitted,

By:



James J. Mullen, III, Ph.D.

Reg. No. 44,957

Morrison & Foerster LLP

3811 Valley Centre Drive, Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-7940

Facsimile: (858) 720-5125

Form PTO-1449

Docket Number 219002030902

Application Number 10/749,706

INFORMATION DISCLOSURE CITATION
ON AN APPLICATION

Applicant

George F. SCHREINER et al.

Filing Date December 31, 2003

Group Art Unit 1647

Mailing Date July 29, 2004

AUG 03 2004

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	06/1984	4,456,550	Dvorak et al.	424	158.1	
	2.	03/1993	5,194,596	Tischer et al.	530	399	
	3.	06/1993	5,219,739	Tischer et al.	435	64.4	
	4.	08/1993	5,240,848	Keck et al.	435	354	
	5.	07/1994	5,332,671	Ferrara et al.	435	360	
	6.	03/2002	6,352,975	Schreiner et al.	514	12	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	7.	05/1997	EP 0 464 155	Europe			
	8.	05/1998	WO 98/20027	PCT			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	9.	Alon et al. (1995). <i>Nat Med</i> 1:1024-1028.
	10.	Banai et al. (1994). <i>Circulation</i> 89:2183-2189.
	11.	Benjamin et al. (1999). <i>J Clin Invest</i> 103:159-165.
	12.	Concepcion et al. (1998). <i>J Hyperten</i> 16(6):863-870.
	13.	Esser et al. (1998). <i>J Cell Biol</i> 140:947-959.
	14.	Ferrara and Davis-Smyth (1997). <i>Endocrine Rev</i> 18:4-25.
	15.	Gerber et al. (1998). <i>J Biol Chem</i> 273:30336-30343.
	16.	Gerber et al. (1999). <i>Development</i> 126:1149-1159.
	17.	Gordjani et al. (1997). <i>Sem Thromb Hemo</i> 23:281-293.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

AUG 03 2004

Docket Number 219002030902

Application Number 10/749,706

Applicant

George F. SCHREINER et al.

Filing Date December 31, 2003

Group Art Unit 1647

Mailing Date July 29, 2004

- | | |
|-----|--|
| 18. | Habib et al. (1982). <i>Adv Nephrol</i> 11:99-128. |
| 19. | Hariawala et al. (1996). <i>J Surg Res</i> 63:77-82. |
| 20. | Henry et al. (1998). <i>J Am Coll cardio</i> 32(2; Suppl A):65A. |
| 21. | Iruela et al. (1995). <i>Am J Pathol</i> 147:1715-1727. |
| 22. | Johnson and Schreiner (1998). <i>Kidney Int.</i> 52:1169-1179. |
| 23. | Johnson et al. 1992). <i>Hypertension</i> 19:464-474. |
| 24. | Kaplan et al. (1990). <i>Ped Nephrol</i> 4:276. |
| 25. | Kitamura et al. (1998). <i>Exp Nephrol</i> 6:328-336. |
| 26. | Klagsburn and D'Amore (1996). <i>Cytokine and Growth Factor Rev</i> 7:259-270. |
| 27. | Kramer et al. (1997). <i>Kidney Int</i> 51:444-447. |
| 28. | Ku et al. (1993). <i>Am J Physiol</i> 265:H586-592. |
| 29. | Lombardi et al. (1999). <i>Hypertension</i> 33:1013-1019. |
| 30. | Monacci et al. (1993). <i>Am J Physiol</i> 264:C995-C1002. |
| 31. | Nangaku et al. (1997). <i>Kidney Int</i> 52:1570-1578. |
| 32. | Nangaku et al. (1997). <i>Kidney Int</i> 52:182-194. |
| 33. | Nangaku et al. (1998) <i>Curr Opin Nephrol Hyperten</i> 7:457-462. |
| 34. | Neilson and Couser eds (1996). <i>Immunologic Renal Diseases</i> , Lippincott-Raven Philadelphia pp 1161-1181. |
| 35. | Papapetropoulos et al. (1997). <i>Clin Invest</i> 100:3131-3139. |
| 36. | Remuzzi and Ruggenti (1995). <i>Kidney Int</i> 48:2-19. |
| 37. | Roberts and Palade (1995). <i>J Cell Sci</i> 108:2369-2379. |
| 38. | Selke et al. (1996). <i>Am J Physiol</i> 271:H713-H720. |
| 39. | Shulman et al. (1996). <i>J Am Soc Nephrol</i> 7:661-666. |
| 40. | Spyridopoulos et al. (1997) <i>J Mol Cell Cardio</i> 29:1321-1330. [erratum pub (1998) <i>J Mol Cell Cardio</i> 30:897]. |
| 41. | Takeshita et al. (1994). <i>J Clin Invest</i> 93:662-670. |
| 42. | Tuder et al. (1995). <i>J Clin Invest</i> 95:1798-1807. |
| 43. | Voelkel et al. (1996). <i>Ann NY Acad Sci</i> 186:93. |
| 44. | Wu et al. (1996). <i>Am J Physiol</i> 271:H2735-2739. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.